Drug assessment at a glance: A26-64[1]

Aficamten (obstructive hypertrophic cardiomyopathy)

19 October 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A26-64. The GBA decides on the added benefit.

Research question for the benefit assessment

Population	Adults with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy
Intervention	aficamten
Comparator	mavacamten
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects		Informative value of the effects	
Mortality	↔		–	
Morbidity	ø		–	
Symptoms	ø		–	
Health-related quality of life	ø		–	
Side effects	ø		–	
	ø	No (suitable) data	–	Not applicable
	↔	No advantage or disadvantage	★	Low
	↑ / ↓	Small advantage/disadvantage	★★	Moderate
	↑↑ / ↓↓	Moderate advantage/disadvantage	★★★	High
	↑↑↑ / ↓↓↓	Large advantage/disadvantage		

Overall: No advantage or disadvantage

Evidence base and noteworthy aspects

- Evidence base: adjusted indirect comparison according to Bucher, based on the SEQUOIA-HCM study (aficamten [N=142] vs. placebo [N=140]) and the EXPLORER-HCM study (mavacamten [N=123] vs. placebo [N=128]) using the common comparator placebo.

- Only results for the outcome of overall survival were included in the indirect comparison. Further patient-relevant outcomes were either not recorded in both of the studies, or were not suitable for the indirect comparison due to differences in the method of recording between the 2 studies or insufficient certainty of results.

Key study findings

Outcome category Outcome Comparison Study	aficamten/mavacamten N	aficamten/mavacamten Patients with event n (%)	placebo N	placebo Patients with event n (%)	Group difference RR [95% CI]; p-value
Mortality					
All-cause mortality					
aficamten vs. placebo					
SEQUOIA-HCM	142	0 (0)	140	0 (0)	NC
mavacamten vs. placebo					
EXPLORER-HCM	123	0 (0)	128	1 (0.8)	–; 0.515
Indirect comparison using common comparators: aficamten vs. mavacamten					–

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Aficamten (hypertrophe obstruktive Kardiomyopathie); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 01.10.2026]. URL: https://doi.org/10.60584/A26-64

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Aficamten (Hypertrophe obstruktive Kardiomyopathie) [online]. 2026 [Accessed: 01.10.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1350/.

English translations for this project are published at https://www.iqwig.de/en/projects/a26-64.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de